NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
BGM Group Ltd. BGM
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$37.9M
▲ 51.1% vs FY2024
EPS · FY25
$-0.18
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-9.2%
Net margin · FY25
-52.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 37.9M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 53 cents on every revenue dollar this year.
Per share
USD -0.18
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-9.2%
Return on equity, FY2025
ROE
Operating margin-33.2%
Net margin-52.6%
Return on assets-8.2%
Each USD of equity lost 9 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−5.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−16.4%
−5.4%
Returned to shareholders
+19.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.20B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 433.8M
total assets, end of FY2025
Total assetsUSD 433.8M
EquityUSD 390.9M
CashUSD 9.8M
Current ratio1.24×
Equity funds 90% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.1
0.1
0.1
0.0
0.1
Operating income $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−0.18
−0.20
−1.08
0.15
0.09
0.17
0.18
0.17
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
−23
·
·
·
·
14
ROE %
−9.2
−3.4
−16.2
2.0
7.8
22.0
29.7
·
Shares out B
0.20
0.01
0.01
0.01
0.04
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
30 of 30
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed